Sana Biotechnology

### Executive Summary Sana Biotechnology raised $866.6M in a private placement (Form D), likely from existing elite backers Andreessen Horowitz and Sands Capital. The massive raise — among the largest disclosed private biotech rounds — signals strong institutional conviction in synthetic biology and intracellular mRNA delivery, despite no public ticker or disclosed state. First sale was 2025-10-12, placing the raise over 7 months ago. ### Investor Edge Watch for a D/A amendment (amended Form D) or a confidential IPO filing. The size and age of this raise imply Sana may be preparing for a public listing or major partnership. Sophisticated investors should monitor SEC filings for Sana Biotechnology and check clinicaltrials.gov for any pending IND applications. ### Sector capital positioning This is one of the largest single private capital raises in synthetic biology / mRNA delivery, reinforcing massive capital migration into programmable medicine platforms. It signals that top-tier crossover funds are doubling down on preclinical or early-clinical assets with platform potential. ### Convergence Signals No explicit patents, contracts, or legislation mentioned in this filing. However, the intracellular mRNA delivery focus intersects with ongoing FDA modernization efforts for gene therapies and next-gen vaccines — watch for clinical trial announcements, IP filings, or partnership news from Sana in 2026. ### Key Takeaways - $866.6M raised — among largest private synthetic biology financings on record. - Backed by Andreessen Horowitz and Sands Capital, indicating top-tier institutional conviction. - First sale dated 2025-10-12; this may be a stale filing, meaning the company could be nearing a liquidity event. ### Risk Indicators & Flags No regulatory red flags in the filing. However, intracellular mRNA delivery is still nascent and faces high clinical risk. No D/A amendment filed yet — if a subsequent amendment appears with terms changed, it could signal downsizing or restructuring. The company is private with no disclosed state, limiting due diligence transparency. ### Verification & References Verify via SEC EDGAR accession 0001702600-24-20359. Officers/directors listed include Andreessen Horowitz and Sands Capital (as registered persons). Total offering amount (capital raised) is exactly $866,600,000. Form D filed as initial notice, not D/A, so terms likely unchanged. No public ticker — company is private.